Identifying and Developing Breakthrough Medicines
Bexion Pharmaceuticals is a mid-stage clinical company developing life-changing treatments in Oncology and CNS.
The company’s lead compound, BXQ-350, is a novel S1P modulator. With our highly experienced biotech leadership team and expertise in Oncology, we are urgently progressing our pipeline to develop life-changing oncology therapies on our path to becoming a leading biotech/pharmaceutical company.
– WATCH
Learn more about Bexion Pharmaceuticals through our highlights video
– WATCH
Dr. Richard Curry, III Medical Director at CTI and Medical Affairs Advisory at Bexion Pharmaceuticals, Inc. recently presented at the 3rd Annual Glioblastoma Drug Development Summit.
– WATCH
